Prelude Therapeutics (PRLD) Non-Current Deffered Revenue (2025)
Prelude Therapeutics (PRLD) posted Non-Current Deffered Revenue of $1.8 million for Q4 2025.
Prelude Therapeutics (PRLD) Non-Current Deffered Revenue (2025) Analysis & Trends
Prelude Therapeutics has reported Non-Current Deffered Revenue for 1 years, with the latest figure at $1.8 million in Q4 2025.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.8 million (changed N/A YoY) and the FY2025 annual result came in at $1.8 million, changed N/A from the prior year.
- Non-Current Deffered Revenue steadied at $1.8 million in Q4 2025 per PRLD's latest filing.
- Over five years, Non-Current Deffered Revenue peaked at $1.8 million in Q4 2025 and troughed at $1.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.80 Mn |